Company Encyclopedia
View More
name
Spruce Biosciences
SPRB.US
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns.
1.946 T
SPRB.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking373/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-167.93%E
    • Profit Margin-6869.30%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-90.18%E
    • Net Profit YoY-21.44%D
    • Total Assets YoY-76.48%E
    • Net Assets YoY-89.57%E
  • Cash ScoreE
    • Cash Flow Margin-1.46%D
    • OCF YoY-90.18%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreD
    • Gearing Ratio64.83%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Spruce Biosciences | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    SPRB
    +0.31%
    LB filings·
    US
    SPRB
    +0.31%

    Spruce Biosciences | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    SPRB
    +0.31%
    LB filings·
    US
    SPRB
    +0.31%

    Spruce Biosciences Q3 net loss narrows

    Spruce Biosciences reported a Q3 net loss of $8.2 million, a reduction in operating expenses, and secured $50 million in private placement financing. The company anticipates this funding will last into Q4 2026. The average analyst rating is "buy," with a median 12-month price target of $132.00, reflecting a 3.8% increase from its recent closing price of $127.00.

    Reuters·
    US
    SPRB
    +0.31%
    Reuters·
    US
    SPRB
    +0.31%

    Spruce Biosciences Raises $50 Million in Private Placement

    Spruce Biosciences Inc. has completed a $50 million private placement financing with healthcare investors. The company issued 502,181 shares of common stock and prefunded warrants for 233,144 shares, exercisable for five years. The funds will support the advancement of its therapeutic programs. This announcement was published via EDGAR on November 10, 2025.

    Reuters·
    US
    SPRB
    +0.31%
    Reuters·
    US
    SPRB
    +0.31%

    Spruce Biosciences Completes One-for-75 Reverse Stock Split

    Spruce Biosciences Inc. has completed a one-for-75 reverse stock split and resumed trading on the Nasdaq Capital Market under the ticker symbol "SPRB" as of September 2025. This announcement was originally published via Business Wire on November 10, 2025.

    Reuters·
    US
    SPRB
    +0.31%
    Reuters·
    US
    SPRB
    +0.31%
    © 2025 Longbridge｜Disclaimer